Table 5.
Evidence Levels | |
---|---|
We suggest that baseline levels of 25(OH)D should not be routinely assessed in patient candidates for pharmacological treatment for osteoporosis or other metabolic bone disorders (that are mandatorily associated with vitamin D supplementation), unless osteomalacia is suspected. | ⊕⊕ |